<DOC>
	<DOCNO>NCT02279979</DOCNO>
	<brief_summary>The primary objective study ass reasonable safety performance HeartMate PHP provide hemodynamic support 72 hour patient cardiogenic shock require stabilization .</brief_summary>
	<brief_title>Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial</brief_title>
	<detailed_description>The HeartMate PHP catheter-based axial flow pump design provide partial leave ventricular circulatory support . This prospective , nonrandomized , control , single-arm , multi-center , open-label trial evaluate safety performance device patient cardiogenic shock .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Cardiogenic</mesh_term>
	<criteria>1 . Patient indicate leave ventricular support accord current medical guideline ( `` current medical guideline '' applies patient enrol Germany ) 2 . Patient cardiac index &lt; 2.2 L/min/m2 treat least one moderate dose inotrope least one moderate dose vasopressor ( e.g. , milrinone ≥0.3 mcg/kg/min , dopamine &gt; 5 mcg/kg/min , dobutamine &gt; 5 mcg/kg/min ) AND : PCWP &gt; 18 mmHg , AND Systolic blood pressure &lt; 100 mmHg , AND Decreased organ perfusion evidence urine output 50 mL/hr OR increase creatinine 0.3 mg/dl baseline obtain within 2 week , OR cool extremity 3 . Written , sign , date informed consent 1 . Patient &gt; 85 year age 2 . Right ventricular failure require mechanical circulatory support 3 . ST elevation myocardial infarction ( STEMI ) within 30 day procedure 4 . Cardiac arrest within 7 day procedure require CPR 5 . Current treatment mechanical circulatory device IABP , ECMO , centrifugal pump , etc . 6 . Documented acute myocarditis 7 . Active major cardiac rhythm disturbance ( e.g. , ventricular tachycardia , ventricular fibrillation ) . 8 . Hypertrophic disease leave ventricular outflow tract obstruction 9 . Active sepsis define bacteremia , fever ≥ 101.5 degree F 10 . Mural thrombus leave ventricle 11 . History aortic valve replacement 12 . Endstage renal disease require dialysis 13 . Documented presence aortic stenosis ( orifice area 1.5 cm2 less ) 14 . Moderate severe aortic insufficiency ( echocardiographic assessment aortic insufficiency grade 2 high ) 15 . Platelet count &lt; 100,000 16 . Allergy Intolerance heparin , aspirin , clopidogrel , ionic nonionic contrast medium , potentially required anticoagulant antiplatelet therapy drug 17 . Known coagulopathies 18 . Presence risk factor severe liver and/or renal dysfunction 19 . Stroke within 90 day enrollment 20 . Significant peripheral vascular disease 21 . History heparin induce thrombocytopenia 22 . Patient pregnant planning become pregnant study period 23 . Patient breastfeeding . 24 . Any active disease ( e.g. , active cancer ) could affect patient 's participation study , life expectancy le 1 year . 25 . Any active disease investigator determines would make patient inappropriate candidate study . 26 . Participation another clinical study investigational drug device meet primary endpoint</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PHP</keyword>
	<keyword>Cardiogenic Shock</keyword>
	<keyword>Percutaneous</keyword>
	<keyword>Ventricular Assist</keyword>
	<keyword>Heart Pump</keyword>
	<keyword>Catheter</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>